Ezetimibe
40 NDCs across 17 manufacturers|39 Generic,1 Brand
Ezetimibe is used to treat hypercholesterolemia, familial combined hyperlipidemia and hyperlipoproteinemia type II, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Oct 25, 2002, and the first generic was approved Jun 26, 2015. FDA's Orange Book lists 12 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $215 million on Ezetimibe across 8.8 million claims for 2.4 million beneficiaries.
Ezetimibe is available as 40 NDCs from 17 manufacturers (39 generic, 1 brand), with NADAC prices from $0.07 to $13.94 per EA — the most expensive product costs about 209× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
40
39G / 1B
Manufacturers
17
competing in market
Price Spread
$0.07 – $13.94
per EA
7d Activity
avg -1.1% WoW · of 40 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Amneal Pharmaceuticals NY LLC manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Dietary Cholesterol Absorption Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
17 manufacturers producing EZETIMIBE(4 pricing outliers)
Frequently Asked Questions
What is Ezetimibe used to treat?
Ezetimibe is used to treat hypercholesterolemia, familial combined hyperlipidemia and hyperlipoproteinemia type II, per the National Library of Medicine's MED-RT classification.
When did Ezetimibe become available as a generic?
FDA approved the first generic Ezetimibe (ANDA) on Jun 26, 2015. The Orange Book currently lists 12 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Ezetimibe?
In 2024, Medicare Part D spent $215 million on Ezetimibe across 8.8 million claims for 2.4 million beneficiaries.
How many Ezetimibe products are on the market?
The Ezetimibe drug market contains 40 NDCs from 17 manufacturers — 39 generic and 1 brand product.
What is the price range for Ezetimibe?
NADAC reference prices for Ezetimibe range from $0.0667 to $13.9369 per EA — the most expensive product costs about 209× the cheapest.
Is generic Ezetimibe cheaper than brand?
The average generic NADAC for Ezetimibe is $0.0685 per EA, versus $13.9369 for brand-labeled products — brand versions average about 204× the generic price.
Which manufacturers make Ezetimibe?
17 manufacturers list Ezetimibe in NADAC. Ranked by number of NDCs, the largest are Amneal Pharmaceuticals NY LLC (3), Sandoz Inc. (3), Actavis Pharma, Inc. (3), ScieGen Pharmaceuticals Inc. (3), Ohm Laboratories Inc. (3).
How has the price of Ezetimibe changed recently?
Over the past 7 days, 0 Ezetimibe NDCs rose and 32 fell, with a market-wide average change of -1.1%.